Core Viewpoint - Chengda Bio (688739) has signed a strategic cooperation agreement with the Institute of Microbiology, Chinese Academy of Sciences, focusing on the prevention of emerging infectious diseases, particularly vector-borne diseases, and aims to jointly apply for national and provincial research projects [1][2]. Group 1: Strategic Cooperation - The agreement emphasizes collaboration in the field of emerging infectious disease prevention, leveraging both parties' resources and expertise to enhance research and development efforts [1]. - Chengda Bio and the Institute of Microbiology will establish a long-term partnership to share resources and amplify their respective strengths in vaccine and biopharmaceutical development [1][2]. Group 2: Research and Development Focus - The collaboration will focus on joint research projects targeting vector-borne disease prevention, with plans to apply for government support and resources to foster innovation [1]. - The strategic partnership aims to accelerate the development of vaccines and biopharmaceuticals for emerging infectious diseases, enriching Chengda Bio's innovation pipeline [2]. Group 3: Intellectual Property and Confidentiality - Each party retains ownership of their respective intellectual property, with jointly developed project outcomes being co-owned as per specific agreements [2]. - Both parties will maintain confidentiality regarding project details and proprietary technologies throughout the collaboration [2].

Core Insights - Chengda Biologics (688739.SH) has signed a strategic cooperation agreement with the Institute of Microbiology, Chinese Academy of Sciences, focusing on emerging infectious diseases [1] - The collaboration aims to jointly apply for national and provincial-level research projects, enhancing efforts in infectious disease prevention and control [1] - This strategic partnership integrates top resources in pathogen research from the Institute of Microbiology with the existing vaccine development platform of the company, accelerating the development of vaccines and biopharmaceuticals for emerging infectious diseases [1]